Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active | |||
Jemperli | dostarlimab | Endometrial cancer | Active | |||
Libtayo | cemiplimab | Locally advanced or metastatic NSCLC (first line) | Active | |||
Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Active | |||
Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | |||
Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active | |||
Slynd | drospirenone | Contraceptive, oral | Reimburse with clinical criteria and/or conditions | Active | ||
Lonsurf | trifluridine and tipiracil | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Active | ||
Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Active |